-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis, Profound Therapeutics Enters Cardiovascular Medicine Development Partnership

MT Newswires·06/26/2025 08:25:08
Listen to the news
08:25 AM EDT, 06/26/2025 (MT Newswires) -- Pharmaceutical company Novartis (NOVN.SW) and ProFound Therapeutics signed a four-year partnership to develop cardiovascular disease drugs. The collaboration will leverage Profound Therapeutics' ProFoundry platform to identify novel proteins to develop the medicine, according to a Thursday release. ProFound Therapeutics will receive an upfront payment of $25 million, and downstream milestones of $750 million per selected target, as well as additional potential for tiered royalties.